Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

Last updated: March 27, 2017
Sponsor: New York Presbyterian Hospital
Overall Status: Completed

Phase

3

Condition

Cervical Dysplasia

Cervical Intraepithelial Neoplasia

Treatment

N/A

Clinical Study ID

NCT00212381
9218
  • Ages 18-80
  • Female
  • Accepts Healthy Volunteers

Study Summary

To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Non pregnant women greater than or equal to 18 years of age able to consent

  • CIN II or III confirmed by histology

  • Karnofsky performance status >= 80

  • No prior treatment for dysplasia in the past 4 months

Exclusion

Exclusion Criteria:

  • Incompletely visible lesion

  • Diethylstilbestrol (DES) exposure

  • HIV seropositive

Study Design

Total Participants: 62
Study Start date:
September 01, 2000
Estimated Completion Date:
July 31, 2010

Study Description

To determine if the use of oral Diindolylmethane (DIM), a marketed cruciferous vegetable based dietary supplement (BioResponse-DIM®), is associated with the regression of cervical dysplasia in otherwise healthy women. Additionally, the study aims to see how the use of the BioResponse-DIM supplement correlates with cervical HPV colonization, and to asses the tolerability of daily DIM supplementation

Connect with a study center

  • NYU School of Medicine

    New York, New York 10016
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.